SLC6A3 and myeloid sarcoma: Post-hoc analyses showed that effects were only significant in female MS groups, where females with prior exposure to MS showed reduced DAT1 following mTBI (p < 0.001) and surgery (p < 0.001) in comparison to sham groups.